Skip to content

Influence of Injection Technique of Premixed Insulin on Glucose Excursion in Type 2 Diabetes Mellitus

Study The Influence of Injection Technique of Premixed Insulin on Glucose Excursion in Type 2 Diabetes Mellitus

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015849
Enrollment
Unknown
Registered
2018-04-24
Start date
2018-04-27
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

1:patient inject insulin themselves
2:nurse inject insulin

Sponsors

Nanjing First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Voluntary participation and signing of consent prior to trial; 2. Patients with type 2 diabetes, according to the WHO 1999 diagnostic criteria, who treated with premixed insulin(pen syringes) monotherapy and/or premixed insulin combined with oral antidiabetic drugs and the treatment was stable for more than three months; 3. Fasting glucose between 6.1-16 mmolL, postprandial(or random) glucose below 22.2mmol/L; 4. No acute complications such as diabetic ketoacidosis, diabetic hypertosmolar syndrome; 5. Subjects were able and willing to ues CGMS and eat regularly. Patients who were able to inject insulin themselves or actual injections can be accompanied.

Exclusion criteria

Exclusion criteria: 1. Insulin allergy; 2. The ALT of liver and kidney function was 2.5 times higher than the normal value. Serum creatinine was 1.3 times higher than the normal value; 3. There has been a history of drug abuse and alcohol dependence in the past five years, or systemic hormone therapy within 3 months; 4. Patients with poor compliance and irregular eating and exercise. Infection or stress within four weeks. Patients unable to tolerate CGMS. Pregnant, lactation or intentionally pregnant. Any other obvious condition or combination of diseases determined by the researcher: such as severe cardiopulmonary, endocrine, neurological, oncological,or a history of mental illness.

Design outcomes

Secondary

MeasureTime frame
insulin antibody;

Primary

MeasureTime frame
MAGE;HbA1C;

Countries

China

Contacts

Public ContactJianhua Ma

Nanjing First Hospital

majianhua196503@126.com+86 18951670116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026